Moderna's personalised mRNA cancer vaccine cuts melanoma death or recurrence risk by 42%, trial shows

Summary

An mRNA cancer vaccine slashes the risk of melanoma death or recurrence by 42%, The Independent reported on Thursday 22 October, Moderna CEO Stephane Bancel saying that the findings herald a new chapter in treating cancer. The Independent also reported that the first-of-its-kind vaccine is helping significantly reduce the chances that melanoma patients' tumors return. On Friday 23 October Nature reported that long-awaited results from a phase III trial show a huge benefit, the Moderna mRNA vaccine almost halving the risk of skin cancer returning, and The Guardian that the trial results represent a 'foundational shift' in the approach to cancer, allowing scientists to harness the immune system in a more personalised way. The Evening Standard and The Independent reported that the world's first mRNA cancer jab for melanoma cuts the risk of death by 42%, the study having included more than 1,100 people with high-risk melanoma that had been surgically removed, and The Independent that melanoma, the most aggressive form of skin cancer, causes about 2,600 deaths a year in the UK.

Latest: The world's first mRNA cancer jab for melanoma cuts the risk of death by 42%, the Evening Standard and The Independent reported, the study having included more than 1,100 people with high-risk melanoma that had been surgically removed, Nature reporting that phase III results show the Moderna mRNA vaccine almost halves the risk of skin cancer returning and The Guardian that the results represent a 'foundational shift' in the approach to cancer.

Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.